WTO Decision On Access To COVID-19 Vaccines: A Waiver In Name Only?
Agreement Could Be Extended To Medicines And Diagnostics In Six Months
R&D-based companies have denounced what they see as a dangerous and unjustified attack on intellectual property after the World Trade Organization’s ministerial conference finally adopted a decision on an IP waiver for COVID-19 vaccines. NGOs, by contrast, say the decision amounts to little more than a limited exception to existing rules on the compulsory licensing of medicines.
You may also be interested in...
Pfizer Adds Hundreds Of Drugs To Global Health Equity Initiative
Pfizer has added hundreds of off-patent products to the portfolio that it is offering on a not-for-profit basis to 45 lower-income countries under its global health equity initiative.
UK Industry ‘Struggling’ With Skill Gaps In AI, Robotics & Data Analytics
A new report says that pharma firms are finding it difficult to recruit staff with experience in emerging scientific technologies, particularly in areas such as regulatory and quality assurance. COVID-19, Brexit and competition for talent with other countries and industry sectors are cited as key factors.
Canada Proposes List Of ‘Critical Products’ & More Agile Regulation To Address Shortages
The Canadian government says stakeholders are “poised for action” to improve the collective response to medical product shortages and has come up with some questions and possible answers as to how best to go about it.